image: Corrected iPS-derived cell therapy for patients with dystrophic epidermolysis bullosa using therapeutic reprogramming. Donor cells are reprogrammed into iPS cells and then genetically corrected by homologous recombination. Corrected iPS cells are sequenced and clones at low risk for skin cancer (green clone) are chosen for in vitro expansion and differentiation into numerous human skin grafts. This image relates to a paper that appeared in the Nov. 26, 2014, issue of Science Translational Medicine, published by AAAS. The paper, by Dr. V. Sebastiano at Stanford University in Stanford, Calif., and colleagues was titled, 'Human COL7A1-corrected induced pluripotent stem cells for the treatment of recessive dystrophic epidermolysis bullosa.' view more
Credit: Artwork by MaryAnn Wijtman Graphics